IL Group Delivers Tamper-Evident Labeling Solution for Prefilled Syringe Launch

IL Group, a specialist in multifunctional labeling solutions for the pharmaceutical and healthcare sectors, has helped Exela Pharma Sciences, a U.S.-based specialty pharmaceutical CDMO, launch a series of prefilled syringe products requiring tailored tamper-evident solutions.

The partnership eliminated a significant hurdle in Exela’s go-to-market timeline, providing a custom-designed label that addressed regulatory and safety requirements, and was compatible with the company’s existing production processes.

The challenge arose as Exela prepared to introduce several new products in plastic cyclic olefin copolymer (COC) syringes. These syringes did not include a manufacturer pre-installed tamper evident feature – an essential safety element for regulatory approval and patient assurance.

Drawing on IL Group’s portfolio of shrink label materials and in-house design expertise, IL Group developed a custom label compatible with Exela’s current labeling operations, avoiding the need for equipment modifications. Featuring a tamper-evident seal tailored to the syringe format, the design was delivered on a tight turnaround to help keep the product launch on schedule.

“Our collaboration with IL Group solved a critical packaging challenge in a condensed timeframe,” said Phanesh Koneru, Ph.D., J.D., LL.M., President and CEO of Exela Pharma Sciences. “They provided not just materials, but true design support – something we could not find elsewhere in the U.S. market.”

Since the launches, Exela has been able to meet growing demand for therapies delivered via prefilled syringes.